Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

About this update from Gain Therapeutics, Inc.

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of an oral presentation at the 3rd International GBA1 Meeting 2026, held May 22-23, 2026, in Phoenix, AZ. The oral presentation outlined new clinical data from the Phase 1b study of GT-02287 further supporting disease-modifying potential in both idiopathic and GBA1 Parkinson’s disease (PD). Gene Mack, President and CEO of Gain Therapeutics, stated, “These longer-term data continue to strengthen our belief that GT-02287 will be among the first therapies, if not the first, to slow or stop the progression of Parkinson’s disease and address the underlying biology causing PD symptoms. We continue to observe overall stability and durability in MDS-UPDRS scores associated with GT-02287 administration in the ongoing Phase 1b study. While we continue to track a potential variation in treatment response related to baseline GluSph in cerebrospinal fluid, we have also been further encouraged by the consistency in feedback among trial participants across different clinical sites regarding improvement in smell and taste, balance or gait, and sleep that we are incorporating as secondary endpoints into our upcoming Phase 2 study to help further understand how different baseline characteristics of Parkinson’s may drive the progression of symptoms.” The oral presentation, titled, “An update on the development of the GCase modulator GT-02287 for Parkinson’s disease,” was delivered by the Company’s Chief Medical Officer Jonas Hannestad, M.D., Ph.D. The data presented, which includes safety, tolerability, biomarkers, and clinical scores from the Phase 1b nine-month study extension support continued development of...

View stock analysis, news, and events for Gain Therapeutics, Inc.